XBIT Stock Forecast: XBiotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.73
+2.98% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$51.2M
Ticker Nerd rank
30/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$6.1M
Net income−$6.7M
Free cash flow−$4.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.7%
1M
−14.4%
YTD
−27.6%
1Y
−22.1%
From 52W high
−36.2%
From 52W low
+3.0%
$1.68
$2.71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores XBiotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Issuance
70
Accruals
63
Momentum
43
Quality
35
Revisions
20
Value
18
Growth
14

Volatility (78): The share price has been relatively steady.

Growth (14): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XBIT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XBIT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.60$1.80$2.00$2.20$2.40$2.60Jan 26Apr 26Jul 26Oct 26XBIT

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Apr 2020Piper SandlerMaintainsOverweight$28 → $18
11 Dec 2019Piper SandlerMaintainsOverweight—
11 Dec 2019PiperJaffrayMaintainsOverweight—
14 June 2019Piper JaffrayInitiatesOverweight—
14 June 2019Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XBIT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XBIT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, XBiotech, Inc. returned −22.1% against +6.9% for the S&P 500, dividends included.

XBIT vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26XBITS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XBIT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.4×

Cheaper than 90% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−29.9%

Higher than 28% of US stocks

Return on assets
−19.3%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • XBiotech, Inc. has a market value of $51.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$45.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$40.8M.

  • Shares outstanding: 30.5M.

  • forward P/E: 13.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • XBiotech, Inc. employs 87 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XBIT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XBITXBiotech, Inc.$51.2M30
XLOXilio Therapeutics, Inc.$53.4M68
NORDNordicus Partners Corp.$54.4M25
BOLDBoundless Bio, Inc.$54.8M93
AVXLAnavex Life Sciences Corp.$54.8M20
ALDXAldeyra Therapeutics, Inc.$50.7M60
OKYOOKYO Pharma Ltd.$55.0M26

Take a look at XBIT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own XBiotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XBIT

How does Ticker Nerd's model rank XBIT?

As at 21 Nov 2026, XBiotech, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

What is the XBIT stock forecast for 2030?

No analyst covering XBiotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIT are extrapolating price history, which says nothing about the business.

How has XBIT stock performed over the past year?

XBiotech, Inc. returned -22.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does XBiotech, Inc. do?

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing True Human™ monoclonal antibodies for a range of diseases. Its current programs center on therapeutic antibodies derived from naturally occurring human immunity, with a pipeline that targets inflammatory, infectious, and oncology-related conditions.

Company

About XBiotech, Inc.

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing True Human™ monoclonal antibodies for a range of diseases. Its current programs center on therapeutic antibodies derived from naturally occurring human immunity, with a pipeline that targets inflammatory, infectious, and oncology-related conditions. The company’s product development efforts emphasize antibody-based treatments designed to address diseases driven by immune and inflammatory pathways, including areas such as cancer, rheumatology, and infectious disease. XBiotech Inc. also supports the clinical and preclinical advancement of candidate therapies built around its proprietary antibody platform. Headquartered in Austin, Texas, XBiotech Inc. operates as a research-driven company within the biotechnology sector, where it contributes to the development of next-generation biologic medicines for unmet medical needs.

CEO Dr. Sushma Shivaswamy Ph.D. · 87 employees · United States · https://www.xbiotech.com